CARC-101C engineered red blood cells
What it is
An early registered study of engineered red blood cells in recent-onset autoimmune T1D. The public record remains not yet recruiting and has no posted outcomes; current programme activity is uncertain.
Editorial review: . What was checked and what remains uncertain.
Latest dated source in the citation list: 2024-08-09. This is the source’s date, not a new review of every claim.
Trial status, labels and access can change between reviews.
Evidence behind this assessment
Key evidence notes. Study results, product eligibility and access answer different questions.
- Who was studied?
- Study populations and analysis groups vary. Product age limits alone do not describe who was studied.See the linked studies and their populations →
- Benefit or performance
- Beta-cell preservation: No clinical preservation result is posted for this programme.[1]
- Important harms and treatment burden
- Safety: The study is designed to assess safety; no programme-specific adverse-event results are posted.[1]
- Approval and country access
- An early registered study of engineered red blood cells in recent-onset autoimmune T1D. The public record remains not yet recruiting and has no posted outcomes; current programme activity is uncertain.Approval, trial recruitment, local supply and funding are separate. Check the cited label or access source.
- Follow-up and remaining uncertainty
- Durability: Lasting immune control or insulin independence has not been demonstrated in the registry.[1]
Research status alone does not establish approval, clinical benefit or local availability.
Editorial score: calculation and evidence
A weighted editorial judgment on a 0–100 scale, not a probability of success or a measured treatment effect. Higher criterion scores mean more favorable assessments.
Default calculation: 10 × 30 + 8 × 20 + 20 × 20 + 25 × 10 + 15 × 20 = 1410; divide by total weight 100. Unrounded weighted result: 14.1.
Lasting immune control or insulin independence has not been demonstrated in the registry.[1]
The study is designed to assess safety; no programme-specific adverse-event results are posted.[1]
The protocol selects adults 18–40 diagnosed 3–6 months earlier, with insulin autoantibodies documented at diagnosis and residual C-peptide.[1]
Evidence is limited to an early registered study; planned enrolment is not a treated or analyzed cohort.[1]
The full picture
What the primary record actually identifies
The registered dose groups describe engineered red blood cells (eRBCs). The name CARC-101C should not be interpreted as a CAR-T product. The early Phase 1 study plans 12 adults and examines safety after a single administration, alongside exploratory metabolic and immune measures.1
An old registration is not current access
The latest public update is from August 2024 and still lists not yet recruiting, despite an estimated primary completion in November 2025. No results are posted. This entry preserves a traceable research candidate while making the uncertainty visible; it does not claim the study started, that the product is available, or that it induces immune tolerance in humans.
The registry does not establish the precise antigen payload or a validated clinical mechanism. Programme-specific harms, effectiveness and durability remain unknown.
Sources
- [1]NCT06546436 — study record · registry · 2024-08-09 — Registry update date; retrieved 16 September 2026. Registry registration is not proof of clinical benefit.